doi:10.3969/j.issn.1004-583X.2024.09.019

Abstract

CLC Number:

R741.041

Add to citation manager EndNote|Ris|BibTeX

URL: https://lchc.magtechjournal.com/EN/10.3969/j.issn.1004-583X.2024.09.019

https://lchc.magtechjournal.com/EN/Y2024/V39/I9/861

References 37

[1]	Furlong Y, Koonamave RL, Sarich E, et al. Refractory case of Tourette's syndrome treated successfully with comprehensive behavioural therapy and aripiprazole[J]. J Paediatr Child Health, 2022, 58(3):539-541.
[2]	Zilhão NR, Padmanabhuni SS, Pagliaroli L, et al. Epigenome-wide association study of tic disorders[J]. Twin Res Hum Genet, 2015, 18:1-11.
[3]	Mohr P, Masopust J, Kopeček M. Dopamine Receptor Partial Agonists:Do they differ in their clinical efficacy?[J]. Front Psychiatry, 2022, 12:781946.
[4]	Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors[J]. J Pharmacol Exp Ther, 2002, 302:381-389. doi: 10.1124/jpet.102.033175 pmid: 12065741
[5]	Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor[J]. Eur J Pharmacol, 2022, 441(3):137-140.
[6]	Carlsson A. Dopamine receptor agonists: Intrinsic activity vs. state of receptor[J]. J Neural Transm, 1983, (57):309-315.
[7]	Janik P, Szejko N. Aripiprazole in treatment of Gilles de la Tourette syndrome-New therapeutic option[J]. Neurol Neurochir Pol, 2018, 52:84-87.
[8]	Lamothe H, Schreiweis C, Mondragón-González LS, et al. The Sapap3-/- mouse reconsidered as a comorbid model expressing a spectrum of pathological repetitive behaviours[J]. Transl Psychiatry, 2023, 13(1):26.
[9]	辛莹莹, 石亮, 梅艳. 阿立哌唑治疗抽动障碍的药动学研究进展[J]. 药物流行病学杂志, 2023, 32(2):221-224.
[10]	Bachmann CJ, Rieger-Gies A, Heinzel-Gutenbrunner M, et al. Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia[J]. Ther Drug Monit, 2008, 30: 462-466. doi: 10.1097/FTD.0b013e318178e18d pmid: 18641558
[11]	Janik P, Szejko N. Aripiprazole in treatment of Gilles de la Tourette syndrome-new therapeutic option[J]. Neurol Neurochir Pol, 2018, 52(1):84-87.
[12]	Kirschbaum KM, Müller MJ, Malevani J, et al. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects[J]. World J Biol Psychiatry, 2008, 9(3):212-218.
[13]	Xin Y, Gao L, Tuo Y, et al. Understanding inter-individual variability in pharmacokinetics/pharmacodynamics of aripiprazole in children with tic disorders: Individualized administration based on physiological development and CYP2D6 genotypes[J]. Front Pharmacol, 2022;13:1048498.
[14]	Seideman MF, Seideman TA. A review of the current treatment of to-urette syndrome[J]. J Pediatr Pharmacol Ther, 2020, 25(5):401-412. doi: 10.5863/1551-6776-25.5.401 pmid: 32641910
[15]	Pozzi M, Pisano S, Bertella S, et al. Persistence in therapy with risperidone and aripiprazole in pediatric outpatients: A 2-year naturalistic comparison[J]. J Clin Psychiatry, 2016, 77(12):1601-1609. doi: 10.4088/JCP.15m10247 pmid: 27780333
[16]	Coustals N, Ménard ML, Cohen D. Aripiprazole in children and adolescents[J]. J Child Adolesc Psychopharmacol, 2021, 31(1):4-32.
[17]	Chevreuil C, Polard E, Lemonnier E, et al. Aripiprazole use in children and adolescent psychiatric patients[J]. Therapie, 2011, 66 (2): 123-130. pmid: 21635859
[18]	Yoo HK, Joung YS, Lee JS, et al. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette’s disorder[J]. J Clin Psychiatry, 2013(74):e772-780.
[19]	Pringsheim T, Holler-Managan Y, Okun MS, et al. Comprehensive systematic review summary: Treatment of tics in people with Tourettesyndrome and chronic tic disorders[J]. Neurology, 2019, 92(19):907-915. doi: 10.1212/WNL.0000000000007467 pmid: 31061209
[20]	Jakobsen KD, Bruhn CH, Pagsberg AK, et al. Neurological, metabolic, and psychiatric adverse events in children and adolescents treated with aripiprazole[J]. J Clin Psychopharmacol, 2016, 36:496-499. doi: 10.1097/JCP.0000000000000548 pmid: 27504593
[21]	Liu Y, Hong N, Wang C, et al. Effectiveness and tolerability of aripiprazole in childrenand adolescents with Tourette’s disorder: A meta-analysis[J]. J Child Adol Psychop, 2015, 26(5):436-441.
[22]	Wichniak A, Samochowiec J, Szulc A, et al. The position statement of the working group of the polish psychiatric association on the use of D2/D3 dopamine receptor partial agonists in the treatment of mental disorders[J]. Psychiatr Pol, 2021, 55(5):941-966. doi: 10.12740/PP/138177 pmid: 34997736
[23]	Rasmussen L, Bilenberg N, Thrane JM, et al. Use of tic-suppressing medication and other psychotropic drugs in children and adolescents with newly diagnosed tic disorders in Denmark[J]. J Child Adolesc Psychopharmacol, 2020, 30(8):476-485.
[24]	Roessner V, Eichele H, Stern JS, et al. European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part Ⅲ: Pharmacological treatment[J]. Eur Child Adolesc Psychiatry, 2022, 31(3):425-441.
[25]	Cox JH, Cavanna AE. Aripiprazole for the treatment of Tourette syndrome[J]. Expert Rev Neurother, 2021, 21(4):381-391. doi: 10.1080/14737175.2021.1893693 pmid: 33612035
[26]	Besag FM, Vasey MJ, Lao KS, et al. Pharmacological treatment for Tourette syndrome in children and adults: What is the quality of the evidence? A systematic review[J]. J Psychopharmacol, 2021, 35(9):1037-1061.
[27]	Hamamoto Y, Fujio M, Nonaka M, et al. Expert consensus on pharmacotherapy for tic disorders in Japan[J]. Brain Dev, 2019, 41(6):501-506.
[28]	Farhat LC, Behling E, Landeros-Weisenberger A, et al. Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: A systematic review and network meta-analysis[J]. Lancet Child Adolesc Health, 2023, 7(2):112-126.
[29]	Murphy TK, Bengtson MA, Soto O, et al. Case series on the use of aripiprazole for Tourette syndrome[J]. Int J Neuropsychopharmacol, 2005, 8(3):489-490.
[30]	Rothenberger A, Roessner V. Psychopharmacotherapy of obsessive compulsive symptoms within the framework of Tourette Syndrome[J]. Curr Neuropharmacol, 2019, 17(8):703-709. doi: 10.2174/1570159X16666180828095131 pmid: 30152283
[31]	Tsai LH, Lin JW, Lee MC. Social communication disorder in an adolescent with ADHD and Tourette's Disorder treated with aripiprazole[J]. Psychiatr Danub, 2022, 34(1):96-99. doi: 10.24869/psyd.2022.96 pmid: 35467619
[32]	Masi G, Pfanner CH, Brovedani P. Antipsychotic augmentation of selective serotonin reuptake inhibitors in resistant tic-related obsessive-compulsive disorder in children and adolescents: A naturalistic comparative study[J]. J Psychiatr Res, 2013, 47(8):1007-1012. doi: 10.1016/j.jpsychires.2013.04.003 pmid: 23664673
[33]	Soltanifar A, Lashkarnevis R, Ziaee M, et al. Investigating the effects and side effects of two antipsychotic drugs in the treatment of children and adolescents with Tourette Syndrome: A semi-experimental research[J]. Curr Drug Discov Technol, 2023, 20(6):1-8. doi: 10.2174/1570163820666230609095720 pmid: 37303178
[34]	张红, 黄海忠, 林国栋. 利培酮与阿立哌唑治疗儿童抽动障碍的随机对照研究[J]. 临床荟萃, 2015, 30(12):1393-1396.
[35]	王鑫, 徐冲锋, 张敏. 阿立哌唑与氟哌啶醇治疗儿童抽动障碍疗效的Meta分析[J]. 中国社区医师, 2018, 34(34):72-75.
[36]	李丹. 阿立哌唑治疗儿童抽动障碍的疗效观察[J]. 中国冶金工业医学杂志, 2024, 41(1):110-111.
[37]	Rizwan M, Shahid NUA, Naguit N, et al. Efficacy of behavioural intervention, antipsychotics, and alpha agonists in the treatment of tics disorder in Tourette's Syndrome[J]. Cureus, 2022, 14(2):e22449.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 37

Related Articles 8

Recommended Articles

Metrics

Comments

[1]	. [J]. Clinical Focus, 2023, 38(11): 1031-1033.
[2]	. [J]. Clinical Focus, 2022, 37(12): 1137-1141.
[3]	Luo Weigang, Yin Yuanyuan, Ren Huiling. Analysis and treatment of primary spinal infection [J]. Clinical Focus, 2022, 37(6): 525-529.
[4]	Lin Xiaoxia, Ke Zhongling, Chen Yanhui, Chen Hui, Chen Xianrui. Meta analysis of the relationship between vitamin D levels and tic disorder [J]. Clinical Focus, 2020, 35(12): 1061-1066.
[5]	. [J]. CLINICAL FOCUS, 2008, 23(14): 1018-1018.
[6]	. [J]. CLINICAL FOCUS, 2002, 17(8): 449-450.
[7]	. [J]. CLINICAL FOCUS, 2002, 17(5): 276-277.
[8]	. [J]. CLINICAL FOCUS, 2002, 17(2): 107-108.